Taking people in FrancePhase 2
Open-Label Access to ATH434 for Patients Who Completed Study ATH434-201 in France
Key facts
- Who runs it
- Alterity Therapeutics
- Where
- Bordeaux, Marseille, Paris, and Toulouse, FranceSee the 4 sites
- Trial code
- Status
- Enrolling by invitation
- Phase
- Phase 2
- People taking part
- 7 people, planned
- Started
- 1 Oct 2026
- Expected to end
- Jul 2029
- Type of study
- Interventional
- Treatments tested
- ATH434
- Record updated
- 9 October 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 4 criteriaShow less
Who can take part
- Completed Alterity protocol ATH434-201
- Expected to benefit from treatment from treatment with ATH434, in the opinion of the Investigator
Who cannot take part
- Discontinued prior ATH434 treatment (ATH434-201) for any reason
- Significant medical or psychiatric condition that may decrease the benefit-risk ratio of participation in this program to an unacceptable level, as per the Investigator's opinion
Where in France
- Centre hospitalier Universitaire de BordeauxBordeaux, FranceTaking people
- Centre Hospitalier Regional De MarseilleMarseille, FranceTaking people
- Assistance Publique Hopitaux de ParisParis, FranceTaking people
- CHU ToulouseToulouse, FranceTaking people
About the trial
What the trial wants to find out
This multicenter open-label extension study conducted in France is designed to provide ATH434 orally BID to eligible patients who completed the Phase 2 study ATH434-201, and who may benefit from this treatment according to the evaluation by the Investigator.
The group in the trial
- ATH434 75mg BIDTreatment being tested
Participants who completed the prior ATH434-201 Phase 2 trial will receive ATH434 75 mg orally twice daily (BID). Treatment consists of an initial 12-month treatment phase, followed by an ongoing extension phase based on investigator assessment of continued clinical benefit, safety, and tolerability
Treatment: ATH434
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).
- Official title
- Open-Label Extension Study to Provide Access to ATH434 in Patients With Multiple System Atrophy
- Record updated
- 9 October 2026